Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44064   clinical trials with a EudraCT protocol, of which   7320   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-003065-95
    Sponsor's Protocol Code Number:AS0011
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-05-21
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2017-003065-95
    A.3Full title of the trial
    A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE
    EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS
    ÉTUDE DE PHASE 3, MULTICENTRIQUE, RANDOMISÉE, EN DOUBLE AVEUGLE, CONTRÔLÉE PAR PLACEBO, DESTINÉE À ÉVALUER L’EFFICACITÉ ET LA TOLÉRANCE DU BIMÉKIZUMAB CHEZ DES PATIENTS PRÉSENTANT UNE SPONDYLARTHRITE ANKYLOSANTE ACTIVE
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to evaluate the efficacy and safety of bimekizumab in subjects with active ankylosing spondylitis
    UNE ÉTUDE DESTINÉE À ÉVALUER L’EFFICACITÉ ET LA TOLÉRANCE DU BIMÉKIZUMAB CHEZ DES PATIENTS PRÉSENTANT UNE SPONDYLARTHRITE ANKYLOSANTE ACTIVE
    A.4.1Sponsor's protocol code numberAS0011
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUCB Biopharma SPRL
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUCB Biopharma SPRL
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUCB BIOSCIENCES GmbH
    B.5.2Functional name of contact pointClin Trial Reg & Results Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressAlfred-Nobel-Strasse 10
    B.5.3.2Town/ cityMonheim
    B.5.3.3Post code40789
    B.5.3.4CountryGermany
    B.5.6E-mailclinicaltrials@ucb.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebimekizumab
    D.3.2Product code UCB4940
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBIMEKIZUMAB
    D.3.9.1CAS number 1418205-77-2
    D.3.9.2Current sponsor codeUCB4940
    D.3.9.4EV Substance CodeSUB130157
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number160
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSuspension for injection in pre-filled syringe
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Ankylosing spondylitis
    Spondylarthrite ankylosante
    E.1.1.1Medical condition in easily understood language
    Ankylosing spondylitis or AS, is a form of arthritis that primarily affects the spine and sacroiliac joints, although other joints can become involved.
    La spondylarthrite ankylosante ou SA, est une forme d'arthrite affectant principalement le rachis et les articulations sacro-iliaques, bien que d'autres articulations puissent être impliquées.
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10002556
    E.1.2Term Ankylosing spondylitis
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Demonstrate the efficacy of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS)
    Démontrer l’efficacité du bimékizumab administré par voie sous-cutanée (sc) toutes les 4 semaines (Q4S) par rapport au placebo dans le traitement de patients ayant une spondylarthrite ankylosante (SPA) active.
    E.2.2Secondary objectives of the trial
    - Assess the efficacy of bimekizumab compared to placebo
    - Assess the safety and tolerability of bimekizumab
    - Assess the impact of bimekizumab on patient-reported quality of life
    - Assess the impact of bimekizumab on spinal mobility
    - Assess the impact of bimekizumab on enthesitis and on peripheral arthritis
    -Évaluer l’efficacité du bimékizumab par rapport au placebo
    -Évaluer la tolérance et la sécurité d’emploi du bimékizumab
    -Évaluer l’impact du bimékizumab sur la qualité de vie rapportée par le patient
    -Évaluer l’impact du bimékizumab sur la mobilité rachidienne
    -Évaluer l’impact du bimékizumab sur les enthésites et l’arthrite périphérique
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    There will be two optional substudies: a pharmacogenomic substudy and a magnetic resonance imaging (MRI) substudy. For subjects consenting to the genomics, genetics, and proteomics substudy, blood samples and stool samples will be drawn for exploratory genetic/epigenetic, genomic, proteomic, and metabolomics analysis and for candidate exploratory biomarker analyses. For subjects participating in the MRI substudy further sacroiliac joint and spine MRIs will be performed.
    Il y aura 2 sous-études opionnelles: une sous-étude de pharmacogénétique et une sous-étude d'imagerie par résonnance magnétique (IRM). Pour les patients ayant consentis à la sous-étude de génomiques, génétiques, et protéomiques, des échantillons sanguins et des échantillons de selles seront prélevés pour des explorations génétique/épigénétique, génomique, protéomique, et des analyses métabolomiques et des analyses de recherche de biomarqueurs exploratoires pour les candidats. Pour les patients participants à la sous-étude IRM, des IRMS additionennelles des articulations sacro-iliques et rachidiennes seront effectuées.
    E.3Principal inclusion criteria
    -Male or female patients at least 18 years of age
    -Subject has ankylosing spondylitis as per the Modified New York (mNY) criteria with documented radiologic evidence, and at least 3 months of symptoms with age at symptom onset less than 45 years
    -Subjects has moderate-to-severe active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >=4 AND spinal pain >=4 on a 0 to 10 Numeric Rating Scale
    -Patients must have inadequate response to NSAIDs, intolerance to administration of at least 1 NSAID, or contraindication(s) to NSAID therapy
    -Patients who have taken a tumor necrosis factor alpha (TNFα) inhibitor must have experienced an inadequate response or intolerance to treatment given at an approved dose for at least 12 weeks
    -Patients currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics, corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry
    -Hommes ou femmes âgés d’au moins 18 ans
    -Patient ayant une SPA d’après les critères modifiés de (mNY, Modified New York) incluant les preuves radiologiques documentées et l’existence d’au moins 3 mois de symptômes avec un âge < 45 ans
    -Atteinte active modérée à sévère, telle que définie par le Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
    -≥ 4 ET rachialgie ≥ 4 sur une échelle d’évaluation numérique (EEN) de 0 à 10)
    -Les patients devront avoir une réponse inappropriée au traitement par AINS ou Intolérance à l’administration d’au moins 1 AINS ou Contre-indication(s) au traitement par AINS
    -Les patients ayant pris un inhibiteur de TNFα doivent avoir présenté une réponse inappropriée à un traitement précédent administré à un dose approuvée pendant au moins 12 semaines ou avoir présenté une intolérance au traitement.
    -Les patients prenant actuellement des AINS, des inhibiteurs de cyclooxygénase 2 (COX-2), des analgésiques, des corticostéroides, des methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) ET/OU aprémilast peuvent être autorisés si les critères requis avant l'entrée dans l'étude sont respectés.
    E.4Principal exclusion criteria
    -Total ankylosis of the spine
    -Treatment with more than 1 TNFα inhibitor and/or more than 2 additional non-TNFα biological response modifiers, or any interleukin (IL)-17 biological response modifier at any time are excluded
    -Active infection or history of recent serious infections
    -Viral hepatitis B or C or human immunodeficiency virus (HIV) infection
    -Any live (includes attenuated) vaccination within the 8 weeks prior to entering the study or TB (Bacillus Calmette-Guerin) vaccination within 1 year prior entering the study
    -Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or current or history of nontuberculous mycobacterium (NTMB) infection
    -Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma or in situ cervical cancer
    -Diagnosis of inflammatory conditions other than AxSpA, eg, rheumatoid arthritis. Patients with a diagnosis of Crohn’s disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease when entering the study
    -Presence of active suicidal ideation, or moderately severe major depression or severe major depression
    -Female patients who are breastfeeding, pregnant, or planning to become pregnant during the study
    -Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
    -Présence d’une ankylose totale du rachis
    -Antécédents à tout moment de traitement par plus d’1 inhibiteur de TNFα et/ou plus de 2 modificateurs supplémentaires de la réponse biologique non-TNFαou tout modificateur de la réponse biologique IL-17 sont exclus
    -Infection active ou antécédents de récentes sérieuses infections
    -Virus de l’hépatite B ou C ou le virus de l’immunodéficience humaine (VIH)
    -Administration d’un vaccin vivant (y compris atténué) au cours des 8 semaines précédant la visite d’inclusion ou antécédents de vaccination par le BCG (Bacille Calmette-Guérin) au cours de l’année précédant la visite d’inclusion
    -Infection tuberculeuse (TB) connue, risque élevé d’acquisition d’une infection TB ou présence en cours ou passée d’une infection à mycobactérie non tuberculeuse (NTMB, nontuberculous mycobacterium)
    -Présence d’un cancer actif ou antécédents de cancer actif dans les 5 années précédant la visite de sélection SAUF carcinome spinocellulaire ou basocellulaire de la peau, ou cancer du col de l’utérus in situ, traité et considéré comme guéri
    -Diagnostic de pathologies inflammatoires autres que SPA, y compris notamment polyarthrite rhumatoïde, sarcoïdose, lupus érythémateux disséminé et arthrite réactionnelle. Un diagnostic de maladie de Crohn, rectocolite hémorragique ou autre MII, est autorisé en absence de maladie symptomatique active lors de la sélection ou de l’inclusion
    -Présence en cours d’idées suicidaires, ou dépression majeure modérément sévère ou dépression majeure sévère
    -Allaitement ou grossesse en cours ou prévision de grossesse pendant l’étude
    -Antécédents d’alcoolisme ou de toxicomanie au cours des 6 mois précédant la sélection
    E.5 End points
    E.5.1Primary end point(s)
    Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 16
    Réponse ASAS40 (critère de la SpondyloArthritis International Society signifiant une amélioration de 40 % à la Semaine 16
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline, Week 16
    Inclusion, semaine 16
    E.5.2Secondary end point(s)
    1. Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response in TNFα inhibitor-naïve subjects at Week 16
    2. Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 16
    3. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 16
    4. Assessment of SpondyloArthritis International Society (ASAS) partial remission (PR) at Week 16
    5. Ankylosing Spondylitis Disease Activity Score major improvement (ASDAS-MI) at Week 16
    6. Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 16
    7. Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
    8. Change from Baseline in nocturnal spinal pain Numeric Rating Scale (NRS) at Week 16
    9. Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 16
    10. Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 16
    11. Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16
    12. Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the subgroup of subjects with enthesitis at Baseline at Week 16
    13. Enthesitis-free state based on the Maastricht Ankylosing Spondylitis Enthesitis Index (MASES) Index in the subgroup of subjects with enthesitis at Baseline at Week 16
    14. Incidence of treatment-emergent adverse events (TEAEs) during the study
    15. Incidence of serious adverse events (SAEs) during the study
    16. Adverse events (AEs) leading to withdrawal from investigational medicinal product (IMP) during the study
    1.Réponse ASAS40 à la Semaine 16 chez des patients naïfs de tout traitement par inhibiteurs de TNFα
    2.Réponse ASAS20 (critère de la SpondyloArthritis International Society signifiant une amélioration de 20 % par rapport à la valeur initiale) à la Semaine 16
    3. Modifications du score BASDAI à la Semaine 16 par rapport aux valeurs initiales
    4.Rémission partielle ASAS (ASAS-PR) à la Semaine 16
    5.Amélioration majeure du score d’activité de la spondylarthrite ankylosante ASDAS-MI (Ankylosing Spondylitis Disease Activity Score major improvement) à la Semaine 16
    6. Évaluation de la réponse ASAS5/6 (amélioration de 5 critères de réponse sur 6 de la SpondyloArthritis International Society) à la Semaine 16
    7.Modifications, par rapport aux valeurs initiales, de l’indice fonctionnel BASFI (Bath Ankylosing Spondylitis Functional Index) à la Semaine 16
    8.Modifications, par rapport aux valeurs initiales, du score EEN de rachialgies nocturnes à la Semaine 16
    9.Modifications, par rapport aux valeurs initiales, de la qualité de vie liée à la spondylarthrite ankylosante (ASQoL, Ankylosing Spondylitis Quality of Life) à la Semaine 16
    10.Modifications, par rapport aux valeurs initiales, du résumé de la composante physique (PCS, physical component summary) du questionnaire de santé abrégé à 36 rubriques (SF-36, Short Form 36-Item Health Survey) à la Semaine 16
    11.Modifications, par rapport aux valeurs initiales, de l’indice de métrologie BASMI (Bath Ankylosing Spondylitis Disease Metrology Index) à la Semaine 16
    12.Modifications à la Semaine 16 par rapport aux valeurs initiales de l’indice d’enthésites MASES (Maastricht Ankylosing Spondylitis Enthesitis) dans le sous-groupe de patients présentant des enthésites à l’inclusion
    13.État sans enthésites à la Semaine 16, fondé sur l’indice MASES dans le sous-groupe de patients présentant des enthésites à l’inclusion
    14.Incidence des événements indésirables apparaissant sous traitement (EIAT)
    15.Incidence des événements indésirables graves (EIG)
    16.Événements indésirables conduisant à un retrait du ME
    E.5.2.1Timepoint(s) of evaluation of this end point
    1.-13. Baseline, Week 16
    14.-16. From Baseline (Day 1) until Safety Follow-Up (up to Week 72)
    1.-13. inclusion, semaine 16
    14.-16. de l'inclusion (jour 1) jusqu'au suivi à long-terme (jusqu'à semaine 72)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity, Tolerability
    Immunogénécité, Tolérance
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA49
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Bulgaria
    China
    Czech Republic
    France
    Germany
    Hungary
    Japan
    Netherlands
    Poland
    Spain
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    dernière visite du dernier patient
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days25
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days26
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 288
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 12
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 217
    F.4.2.2In the whole clinical trial 300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Eligible subjects will be allowed to enroll in an extension study.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-05-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-06-11
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-08-08
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA